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Objectives: This report summarizes the ﬁrst use of a digital health feedback system (DHFS) by
practicing pharmacists to establish evidence-based blood pressure (BP) management
recommendations.
Setting: Fifteen commercial pharmacies and 39 patients in the Isle of Wight participated.
Practice description: The pharmacists were experienced in providing New Medicine Services to
patients in their communities.
Practice innovation: The pharmacists utilized a commercially available DHFS. The DHFS uti-
lized FDA-cleared and CE-marked class 2 medical devices passively captured and shared in-
formation about medication-taking using an ingestible sensor, and daily patterns of rest,
activity, and exercise using a wearable patch that incorporates an accelerometer.
Interventions: Pharmacists provided targeted counselling for BP management as guided by the
digital information.
Evaluation: Blood pressure was measured serially, and patient and provider experiences with
DHFS use were assessed using satisfaction surveys.
Results: The mean change in SBP over the 2-week evaluation period was -7.9 ± 22.1; mean
change in DBP was -2.8 ± 12.9. A root cause for persistent hypertension was determined for all
of these 34 patients: 68% had pharmaceutical resistance, and 32% had inadequate medication
use. Speciﬁcally, 29% were found to be capable to achieving blood pressure control on their
currently prescribed medications, 68% were found to have a need for additional pharmaco-
logical treatment, and 3% needed additional adherence support. Pharmacists found that the
DHFD helped in targeting speciﬁc recommendations, and to create a collaborative experience
with their patients. Patients found the experience to be positive and helpful.
Conclusion: DHFS that provides conﬁrmation of medication taking and objective measures of
lifestyle patterns can help pharmacists to identify speciﬁc factors contributing to uncontrolled
hypertension, to make evidence-based prescribing and lifestyle recommendations for
achieving treatment goals, and to create a collaborative experience for patients in the man-
agement of their self-care.
© 2016 American Pharmacists Association. Published by Elsevier Inc. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Objectives evidence-based blood pressure (BP) management recom-This report summarizes the ﬁrst use of a digital health
feedback system (DHFS) by practicing pharmacists experi-
enced in providing New Medicines Service (NMS) for com-
munity patients. The DHFS was used by them to establishal Health, 2600 Bridge
ation. Published by Elseviermendations. Patient and provider questionnaires were used
subsequently to assess their experience with DHFS.
Setting
One-third of adults in the United Kingdom have hyper-
tension.1,2 Elevated BP exhibits a strong, positive, and dose-
dependent relationship with the risk of cardiovascular
disease throughout its entire range. The relationship is inde-
pendent from other risk factors, shows no evidence of aInc. This is an open access article under the CC BY-NC-ND license (http://
Key Points
Background:
 The pharmacists of today have become essential
care providers and integral to the patient care team
practice model.
 Community pharmacists are actively involved even
now in initiatives such as the NewMedicines Service
for the management of chronic conditions such as
hypertension.
 A digital health feedback system is available for
providing an objective evidence base that can be
used to make individually tailored medication and
lifestyle recommendations to manage persistent
blood pressure elevation. No extra pharmacist certi-
fications or training is required.
Findings:
 Community pharmacists evaluated its use for
providing targeted counselling for blood pressure
management as guided by the digital information.
 The system helped pharmacists to identify specific
factors contributing to uncontrolled hypertension, to
make evidence-based prescribing and lifestyle rec-
ommendations for achieving treatment goals, and to
create a collaborative experience for patients in the
management of their self-care.
 This paradigm fits well with the National Health Ser-
vice Right Care agenda to deliver value from health
care over the remainder of this decade through evi-
dence-based planning, delivery and monitoring of
health care delivery.
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SCIENCE AND PRACTICEthreshold for risk, and applies to all major manifestations of
cardiovascular disease.3 Current control rates are below the
Healthy People goal of 50%, which was originally set as the
year 2000 goal and has since been extended.4 Poor adherence
to antihypertensive therapy is a major cause of lack of BP
control. A similar problem exists in incorporating lifestyle
modiﬁcation for BP management. In a European survey
involving patients with established heart disease from 15
countries, only 66% practiced a physical activity.5
DHFS has been used previously in primary care practices for
assessing and making evidence-based modiﬁcations in the
treatment of 151 patients with uncontrolled BP while pre-
scribed 2 or more antihypertensives. A root cause for
uncontrolled BP was identiﬁed in 95% of patients: 57% had
pharmaceutical resistance, and 43% had inadequate medica-
tion use. Overall, 38% were found to be capable of achieving BP
control on their currently prescribed medications. Primary
practices found the offering easy to use, and the majority of
patients expressed a positive and collaborative experience in
using it.6
The NMS is a National Health Service (NHS) community
pharmacy service that provides support for people with
long-term conditions newly prescribed a medicine to help
improve medication adherence. Since the introduction of theNMS in October 2011, more than 90% of community phar-
macies in England have provided it to their patients. The
goals of the NMS include supporting patients in making
decisions about their treatment and self-management,
reducing medicine wastage, receiving positive assessment
from patients, improving the evidence base on the effec-
tiveness of the service, and supporting the development of
outcome and/or quality measures for community
pharmacies.7
Among the challenges in meeting these goals is awareness
of actual utilization of prescribed medicine. The NHS is looking
to improve prescribing and dispensing systems, and is
encouraging rational cost-effective prescribing.8 Core to
meeting the objective of evidence-based prescribing is iden-
tifying and targeting those patients who do not take their
medicines appropriately.9 This is a signiﬁcant challenge
because practitioners are unaware of how patients actually
take their medications outside of the clinic.10
Of additional importance is the incorporation of lifestyle
advice for BP control. National Institute for Health and Care
Excellence (NICE) guidelines advise that ascertainment of
exercise pattern and lifestyle advice should be offered initially
and then periodically throughout the life cycle of BP man-
agement.11 Yet, other than self-report, practitioners do not
routinely determine how much patients are actually exer-
cising, much less achieving the British Heart Foundation's
recommended goal of 10,000 steps daily.12
Practice description
This service evaluation occurred in 15 community phar-
macies in the Isle of Wight and included 39 patients with
uncontrolled BP. Pharmacists performed an initial assessment
of needs, made lifestyle recommendations, and administered
antihypertensive therapy that was prescribed per NICE
guidelines. The participating pharmacists who elected to
introduce the DHFS into their practices did not have any extra
certiﬁcations, training, or prior utilization of DHFS, and they
had no characteristics that would differentiate them from the
remainder of the general pharmacist population.
Practice innovation
The DHFS (Proteus Digital Health, Redwood City, CA) uses
Conformite Europeenneemarked type 2 medical devices
consisting of a poppyseed-sized ingestible sensor made of
foodstuff and a wearable sensor (also called “patch”) that may
be utilized for 7-day wear during all activities, including
exercising and bathing.
Description of the ingestible sensor
After entering the stomach, the ingestible sensor uses the
gastric ﬂuid to send a tiny and brief biogalvanic signal. The
signal contains no radiation, is not pH dependent, and lasts
approximately 7 minutes. The remainder of the ingestible
sensor is then inactive and is eliminated like a poppyseed husk
in the feces. More than 500 subjects have ingested more than
20,000 ingestible sensors in clinical studies that have included
subjects with bipolar disorder, diabetes, heart failure, hyper-
tension, renal transplantation, schizophrenia, tuberculosis,311
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SCIENCE AND PRACTICEseniors with fragile skin, and healthy volunteers. No device-
related serious adverse events and no unanticipated adverse
device effects have been reported. The ingestible sensor has
been coingested with more than 400 different drugs without
adverse interaction.13
Description of the patch
The signal from each ingestible sensor is unique and is
recorded by the patch worn on the patient's torso. The patch
can be worn for up to one week during all daily activities,
including exercise and brief shower or bath. It passively and
automatically records and reports: (1) the date, time, type,
and amounts of ingested medicinals; and (2) physiologic data
and habits of daily living. These include daily step count, sleep
duration and quality, and circadian pattern. The patch
passively and automatically transmits its stored data to a
compatible computerized device for display and transmission
to a secure cloud-based server (Figure 1).
Privacy, conﬁdentiality, and anonymity
The information from the patch is made available for
viewingwith the use of a designated app on amobile device or
a secure webpage. All of an individual's information is
encrypted and private; only that individual can determine
who may see it. The data that are stored on the patch are
automatically communicated to a computerized device (e.g., a
smartphone) via encrypted Bluetooth transmission whenever
the patchmay come into rangewith the device. The device can
display the information for the patient, and it forwards the
encrypted information to a secure cloud server, where it can be
monitored by doctors and other caregivers who are authorized
by the patient. An individual's information is secure and
handled in a manner that meets all privacy and information
governance requirements.
Implementation
Participants were introduced to the DHFS as an assess-
ment tool on an ad hoc basis and were not randomized.
Pharmacists instructed patients, who provided written
agreement to use the DHFS, in its use and patch changes.Figure 1. Digital health feedback device fo
312Patients were asked to ingest an inert tablet containing an
ingestible sensor at the time of each of their prescribed
periods of medication dosing. The DHFS was used by phar-
macists to assess individual medication and lifestyle habits of
patients with uncontrolled BP, and they used the information
that was collected by the DHFS to individually tailor recom-
mendations regarding medication use or lifestyle modiﬁca-
tion and to engage patients in their self-care. Using a
paradigm similar to that which was already in existence for
the NMS, patients returned to the community pharmacy after
one and 2 weeks to discuss the information that was collected
by the DHFS. BP was measured at each pharmacy visit per
usual and customary care.
No changes occurred in antihypertensive therapy during
this period. Per guidance in the existing NHS care pathway for
hypertension, a 2-week period was considered to be sufﬁcient
to determine maximal BP response to the prescribed antihy-
pertensive treatment.Interventions
The pharmacists reviewed the BP changes, and the medi-
cation and lifestyle activities as recorded by the DHFS, with
patients at the time of each visit, and provided targeted
counseling as guided by the digital information and BP de-
terminations. Figures, graphs and tables on the mobile dis-
plays summarized daily and cumulative taking adherence,
timing adherence, step count, and hours of sleep and sleep
interruption. Taking adherence consisted of the total number
of ingestible sensors that were detected by the patch, divided
by the total number of doses that were prescribed. Timing
(also known as “scheduling”) adherence consisted of the
number of ingestible sensors that were detected within a ±1-
hour time window around the prescribed dosing time, divided
by the total number of ingestible sensors that were detected
during that dosing interval.
No hypotheses were generated or tested, and no investi-
gational products were used in this evaluation. All physical and
other assessments that occurred were those that are used as
part of usual and customary care. There were no changes in
treatment and patient care from accepted standards for any of
the patients involved. Based on this and other precedents,
there was no requirement for ethics approval.14,15r assessment of hypertension therapy.
Figure 2. (A) Systolic and (B) diastolic blood pressure (BP) changes over
2 weeks.
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Blood pressures and information that was passively
collected by the DHFS, along with pharmacist intervention and
patient feedback data, were stored on an existing Web-based
system already in routine use in the participating commu-
nity pharmacies.
After completion of DHFS use, all patients were interviewed
on site by their respective pharmacists regarding DHFS
usability, and both patients and pharmacists subsequently
completed a written satisfaction survey by mail. Commercial
satisfaction surveys were used. The structure of the interviews
and questionnaires were standardized but not validated sur-
veys, and questions concerned comfort, ease of use, usefulness,
and satisfaction with the pill, patch, and mobile displays.
All analyses for this report were performed subsequently
with the use of anonymized data and standard existing NHS
processes in routine use for assessing NMS care delivery per-
formance. A threshold of 80% was used to deﬁne medication
adherence, because this has been used for a majority of the
studies in the literature on medication adherence, with data
from both observational and randomized controlled clinical
trials.16
Results
Table 1 summarizes the baseline demographics and BPs of
the patients who used the DHFS. Figure 2 summarizes systolic
and diastolic BP changes over 2 weeks. Table 2 summarizes
pharmacist interventions that were made subsequently.
Figure 3 summarizes the results of patient surveys on the
usability and acceptability of the DHFS.
Among the39patientswhoused theDHFS, themeanagewas
60.5 years, the mean baseline systolic BP (SBP) was 154.3 ± 18.9
mm Hg, and mean diastolic BP (DBP) was 88 ± 11.5 mm Hg.
After 2 weeks of use, BP decreased overall among the patients
who used the DHFS. The mean change in SBP over the 2-week
evaluation period was 7.9 ± 22.1 mm Hg; mean change in
DBP was2.8 ± 12.9 mmHg.
Recommendations after DHFS use consisted of increasing
activity level, improving medication adherence, or a combi-
nation of the two. Using a threshold of 80% for medication
adherence, a root cause for persistent hypertension during
existing antihypertensive treatment was determined for all
patients (100%): 68% had pharmaceutical resistance, that is,
they were found during DHFS to be incapable of achieving BP
control on their prescribed antihypertensive medications; 32%
had uncontrolled BP owing to inadequate use of their pre-
scribed therapy.Table 1
Baseline demographics and blood pressures
No. of patients 39
Age (y) 60.5 (32e83)
Smoking status
Smoker 6 (15.6%)
Former smoker 10 (25.4%)
Nonsmoker 23 (59%)
Baseline blood pressure (mm Hg)
Systolic 154 (124e200)
Diastolic 88 (60e116)
Values are presented as mean (range) or n (%).Recommendations for daily exercise were based on the
British Heart Foundation's recommended goal of 10,000 steps
daily to improve health, lose calories, and reduce disease
risks.17 Patients for whom the pharmacists recommended an
increase in physical activity had a lower average step count
recorded than those for whom activity was not part of the
recommendation (10,132 ± 1147 steps vs. 6677 ± 709 steps,
respectively).
Out of 13 pharmacists, 11 were surveyed and found that the
DHFS helped to create a collaborative experience with their
patients; 91% of those surveyed noted that the longitudinal
trends in actual medication use and activity patterns aided
them in counseling and making speciﬁc recommendations. A
majority of patients found the overall usability of the devices
and the app to be good. Of the 15 patients who returned
additional satisfaction surveys by mail, 100% found the expe-
rience to be positive, 87% felt more involved with clinical care,
and 87% also found that the information helped to improve
compliance.Table 2
Pharmacist interventions at weeks 1 and 2, n (%)
Recommendation Week 1 Week 2
No. of patients 35 39
Activity 15 (42.9) 17 (43.6)
Medication adherence 9 (25.7) 7 (17.9)
Activity þ medication adherence 3 (8.6) 2 (5.1)
Other recommendation* 8 (22.9) 13 (33.3)
* Diet (fat, reﬁned sugar, salt reductions), weight loss, smoking cessation,
hours of sleep, etc.
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Figure 3. Results of patient surveys on the usability and acceptability of the
digital health feedback system.
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Hypertension has been highlighted as a key target area for
the NMS, but identifying which patients are not taking medi-
cines properly is a challenge. In hypertension, the most
obvious sign is poorly controlled BP. However, that may also be
due to a worsening of the condition. Although there is a range
of potential interventions that can be used to support patients
with uncontrolled BP, at the core of clinical decisions for in-
dividual management is a need for objective, ready, and
minimally burdensome identiﬁcation of the reason for an in-
dividual being uncontrolled or appearing to require a consid-
erable pharmaceutical burden to achieve control.18,19 The
essential question is whether nonadherence or pharmacologic
unresponsiveness may be the root cause.20
The present report summarizes the ﬁrst use of a commer-
cially available DHFS by practicing pharmacists to establish
evidence-based BP management recommendations. With the
use of the DHFS, community pharmacists were able to identify
a root cause for persistent hypertension for all of the patients
who used the product. Two-thirds were identiﬁed to have
pharmaceutical resistance, and one-third were found to have
inadequate medication use as a root cause for their uncon-
trolled BP. Pharmacists found that the DHFS helped in target-
ing appropriate recommendations, as well as created a
collaborative experience with their patients. Patients found
the experience to be positive and helpful.
Because this was a real-world use of DHFS, a pre-post
assessment was used to determine the relationship between
medication use and ability to control BP. Although this reﬂects
a different perspective from that of a randomized controlled
trial, it nonetheless demonstrates how the product is used in
actual practice. Patients may have increased their adherence
while using the DHFS because of a Hawthorne effect; rather
than a limitation, that actually provided a strength, because it
made it possible to determine whether BP control was actually
achievable on existing treatment. Coingestion of an ingestion
sensor is a surrogate for actual medication ingestion, and pa-
tients may have been selective in the medications that they
actually ingested. Despite this limitation, one-third of patients
with uncontrolled hypertension were identiﬁed as actually
being capable of controlling their BP on their existing therapy.
Experience from this ﬁrst use of DHFS in community
pharmacies builds on the experience of primary care practices
in the recently completed UK Hypertension Registry.6 This ﬁrst
use of DHFS by community pharmacists who currently offer314the NMS demonstrates that they are well placed for including
DHFS in their support for patients.
Application to practice
The role of today's pharmacists in the UK and the USA is
evolving. Once limited to ﬁlling and dispensing prescription
medications, the pharmacists of today have become essential
care providers and integral to the patient care team practice
model. Use of DHFS in this setting provides an objectivemeans
of reviewing medicine adherence and lifestyle. The informa-
tion that is collected by the DHFS can be used to determine the
root cause for uncontrolled hypertension during existing
antihypertensive treatment, thereby providing an evidence
base for appropriate prescribing recommendations, and a
means for avoiding the medicine wastage that would other-
wise occur from unnecessary overprescribing due to persistent
“pseudoresistant” BP elevation.
DHFS also provides ameans for pharmacists to support their
patients in making decisions about lifestyle in addition to their
pharmaceutical treatment. Use of DHFS created a collaborative
experience with patients, and patients found the experience to
be positive and helpful. These experiences are similar to those
that have been reported by primary care practices who partic-
ipated in the UKHypertension Registry6 and that have also been
reported elsewhere when health care practitioners communi-
cate and share complete and unbiased information with pa-
tients and families in ways that are afﬁrming and useful, such
that a shared understanding can occur and facilitate sustained
and meaningful partnership in care.21
No extra pharmacist certiﬁcation or training is required to
use DHFS. In addition to providing an objective evidence base
that can be used to make individually tailored medication and
lifestyle recommendations to manage hypertension, DHFS
data can be incorporated into objective outcome and/or
quality measures when assessing community pharmacy
activities and interventions in supporting patients.
Conclusion
DHFS is a practical and helpful means of assessing medi-
cation taking and objectively measuring of lifestyle patterns,
thereby assisting practicing community pharmacists in iden-
tifying speciﬁc factors contributing to uncontrolled hyper-
tension, making better informed recommendations regarding
treatment escalation, and providing evidence-based lifestyle
recommendations to achieve treatment goals. In addition,
DHFS can create a collaborative, positive, and helpful experi-
ence for patients in managing their self-care.
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